New Lyme disease vaccine could help with disease prevention search.app/fJxgM

#VaccineNews
#LYMEdisease
#Science

1/8 🇨🇦 FLORIDA IS ENDING VACCINE MANDATES 🇨🇦

Doctors warn Canadian travellers about increased disease risks as Florida plans to eliminate childhood vaccine requirements. The move affects millions of visitors, including 3.4 million Canadians in 2024.

Jennifer Yoon reports.
#Florida #VaccineNews

FluMist Home: Flu Vaccine Delivered to Your Door for the First Time Ever Flu Vaccine Delivered to Your Door For the first time in the United States, some adults and children can receive the nasal spray flu vaccine, FluMist, delivered directly to their…

🚨 Breaking News 🚨

FluMist Home Flu Vaccine Delivered to Your Door for the First Time Ever—a New Era in Immunization

South Florida Media - Florida's Free News Leader

Article Link: sfl.media/flumist-home...

#FluMist #HomeDelivery #VaccineNews #BreakingNews #SouthFloridaMedia

Pandemic darlings Moderna, BioNTech are now on two different paths - CNBC Pandemic darlings Moderna, BioNTech are now on two different paths  CNBC

Click Subscribe #Pandemic #Moderna #BioNTech #COVID19 #VaccineNews

The US will stop using flu shots with mercury-based preservative thimerosal, under Health Secretary RFK Jr.’s orders. Though studies showed no harm, anti-vax concerns pushed the move. Vaccine supply to continue without disruption. #VaccineNews #ThimerosalBan #TheWorldPK

Mouse Scientists Outsmart COVID Variants, Mice Demand Nobel Prizes Now #Satire #COVID19 #VaccineNews #Science #MiceTakeOver By: TheJestPress.com **Bold New COVID Vaccine Rocks World of Mice; Humans Jealous** In a breakthrough sure to redefine the landscape of both medical science and rodent wellness, researchers have unveiled a COVID-19 vaccine candidate that offers strong protection across multiple variants—at least if you happen to be a mouse. The new vaccine, ingeniously targeting features shared by a whole range of coronaviruses, promises broad and long-lasting immunity—potentially until the cheese runs out.

Mouse Scientists Outsmart COVID Variants, Mice Demand Nobel Prizes Now

#Satire #COVID19 #VaccineNews #Science #MiceTakeOver By: TheJestPress.com **Bold New COVID Vaccine Rocks World of Mice; Humans Jealous** In a breakthrough sure to redefine the landscape of both medical science and rodent…

✅BREAKING: The RSV vaccine just got the green light!
🗳️ Next up? ACIP votes on the flu shot—and the stakes are high.
Learn about who’s voting, what’s changing, and why it matters on our latest podcast episode 👉 🎧
#RSV #FluShot #VaccineNews #PublicHealth #MedTwitter #ACIP

New CDC Vaccine Advisers Include Vaccine Skeptics and Misinformation Spreaders Kennedy Reshapes CDC Vaccine Panel with Critics of Mainstream Science, Prompting Alarm Among Experts In a sweeping shake-up of federal

New CDC Panel Includes Critics of COVID Shots and Public Health Mandates

#RFKJr #CDC #VaccineNews #PublicHealth #HealthPolicy
#COVID19 #VaccineControversy #Misinformation #HealthUpdate #Immunization

CDC Scales Back COVID Shot Guidance for Healthy Kids and Pregnant Women CDC Quietly Changes COVID-19 Vaccine Guidance for Healthy Kids and Pregnant Women In a subtle but significant shift, the Centers

CDC Updates COVID-19 Vaccine Guidance for Kids and Pregnant Women

#COVID19Vaccine #CDCUpdate #VaccineGuidance #HealthyKids #PregnantWomen #PublicHealth #VaccineNews
#COVID19Update #HealthAdvice #StayInformed

CDC may update 'fully vaccinated' to include boosters. Experts debate timing & impact. Currently, 57% of Americans are fully vaxxed, only 6% boosted.

Read More: internationalnewss.exblog.jp/33665674/

#COVID19 #VaccineNews #CDC #BoosterShot #PublicHealth

Novavax’s COVID shot just got FDA approval—but only for seniors and high-risk groups. Unlike Pfizer/Moderna, it’s off-limits for most healthy under-65s. Why the limits? Click the link for the full story! #COVID19 #VaccineNews scientificinquirer.com/2025/05/19/d...

Novavax shares surge on FDA vaccine approval Investing.com -- Novavax , Inc. (NASDAQ:NVAX) stock soared 12% in response to the U.S. Food and Drug Administration’s approval of the company’s Biologics License Application (BLA) for its COVID-19 vaccine, Nuvaxovid. This approval enables the vaccine’s use for adults over 65 and individuals aged 12 through 64 with certain high-risk conditions, marking a significant expansion of Novavax’s market reach. The FDA’s green light for Nuvaxovid has triggered a $175 million milestone payment from Sanofi (NASDAQ:SNY), under a collaboration and license agreement signed in May 2024. Novavax’s President and CEO John C. Jacobs underscored the approval as a critical step toward providing a protein-based, non-mRNA COVID-19 vaccine option for high-risk populations in the United States. Novavax’s vaccine has been available under Emergency Use Authorization in the U.S. since July 2022 and has garnered full market approvals in several major regions, including the EU, UK, Japan, Canada, Australia, Taiwan, and Singapore. The company is preparing for commercial delivery of the 2025-2026 COVID-19 vaccine formula in the U.S. this fall, in collaboration with Sanofi, pending further FDA recommendations. Wall Street analysts have noted the significance of this approval, stating, "This clears the way for NVAX supply and brand presence this season, with differentiation as the only non-mRNA option to suit various populations including mRNA-intolerant/hesitant people." This sentiment reflects the potential for Novavax to capture a unique segment of the vaccine market. In addition to the immediate financial boost from the milestone payment, Novavax is set to receive ongoing tiered royalties from stand-alone COVID-19 vaccine sales in future vaccination seasons. The FDA has also requested a Phase 4 trial to further assess the vaccine’s efficacy and safety in a broader population, which Novavax plans to undertake in partnership with Sanofi. Investors reacted positively to the news, as the FDA’s approval not only enhances Novavax’s product offering but also solidifies its partnership with Sanofi, a key player in the vaccine market. The company’s stock movement today reflects optimism about its growth prospects and the expanded availability of Nuvaxovid in the U.S. market. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Novavax #FDAApproval #VaccineNews #StockMarket #Investing

Click Subscribe #Novavax #COVID19 #FDAApproval #VaccineNews #Pharmaceuticals

Moderna, Pharma Stocks Fall as FDA Names Industry Critic as Top Vaccine Regulator - Barron's Moderna, Pharma Stocks Fall as FDA Names Industry Critic as Top Vaccine Regulator  Barron's

Click Subscribe #Moderna #PharmaStocks #FDAVaccineRegulator #VaccineNews #Pharmaceuticals

Novavax stock tumbles on HHS comments about vaccine Investing.com -- Novavax (NASDAQ: NASDAQ:NVAX) stock plummeted 24% after comments from Health and Human Services Secretary Robert F. Kennedy Jr. suggested a shift in government priorities away from the company’s vaccine technology. The sharp decline came as Kennedy indicated during a CBS News interview that the U.S. government is moving its focus to vaccines that utilize multiple antigens, rather than the single antigen approach used by Novavax. "We’re looking at that vaccine and it is a single vaccine. And, for respiratory illness, the single antigen vaccines have never worked," Kennedy stated. He further noted, "We’re actually shifting our priorities to multiple antigen vaccines." This news follows Novavax’s announcement last week that it is still awaiting a decision from the FDA regarding its Covid-19 vaccine approval application. Kennedy clarified that the delay in approval was not due to a lack of personnel but rather because of the type of vaccine Novavax produces. The market’s reaction to Kennedy’s remarks was not isolated to Novavax, as shares of other vaccine makers also experienced declines. Moderna (NASDAQ:MRNA) saw an 8% drop, Vir Biotechnology (NASDAQ:VIR) fell 7%, Vaxcyte was down 4.5%, and BioNTech (NASDAQ:BNTX) decreased by 2.5%. Investors are now grappling with the implications of this shift in government strategy for Novavax and its peers in the vaccine industry. As the landscape for Covid-19 vaccine development evolves, companies may need to adjust their approaches to align with new public health strategies and regulatory expectations. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Novavax #VaccineNews #StockMarket #HHS #Biotech